Panbela Therapeutics - PBLA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $500.00
  • Forecasted Upside: 42,272.88%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.18
▼ -0.05 (-4.07%)

This chart shows the closing price for PBLA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Panbela Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PBLA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PBLA

Analyst Price Target is $500.00
▲ +42,272.88% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Panbela Therapeutics in the last 3 months. The average price target is $500.00, with a high forecast of $500.00 and a low forecast of $500.00. The average price target represents a 42,272.88% upside from the last price of $1.18.

This chart shows the closing price for PBLA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Panbela Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/18/2023Roth MkmReiterated RatingBuy ➝ Buy$500.00Low
8/11/2023HC WainwrightReiterated RatingBuy ➝ BuyLow
7/24/2023HC WainwrightReiterated RatingBuy ➝ BuyLow
4/26/2023HC WainwrightReiterated RatingBuyLow
3/20/2023Maxim GroupUpgradeHold ➝ BuyLow
1/31/2023Roth CapitalInitiated CoverageBuy$6,000.00Low
10/12/2022Maxim GroupDowngradeBuy ➝ HoldLow
5/13/2022Maxim GroupInitiated CoverageBuy$120,000.00Low
3/25/2022Maxim GroupInitiated CoverageBuy$120,000.00Medium
2/23/2022Craig HallumBoost Target$216,000.00 ➝ $312,000.00High
6/28/2021Roth CapitalInitiated CoverageBuy$240,000.00High
3/26/2021Maxim GroupInitiated CoverageBuy$192,000.00High
3/10/2021Maxim GroupInitiated CoverageBuy$192,000.00Medium
(Data available from 2/28/2019 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
8/2/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/1/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/1/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/31/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
11/30/2023
  • 3 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
12/30/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
1/29/2024
  • 2 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
2/28/2024

Current Sentiment

  • 2 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Panbela Therapeutics logo
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of Panbela's investigative agent ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Read More

Today's Range

Now: $1.18
Low: $1.17
High: $1.23

50 Day Range

MA: $7.85
Low: $1.11
High: $24.00

52 Week Range

Now: $1.18
Low: $1.06
High: $720.00

Volume

125,238 shs

Average Volume

972,436 shs

Market Capitalization

$306.80 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Panbela Therapeutics?

The following equities research analysts have issued research reports on Panbela Therapeutics in the last twelve months: HC Wainwright, Maxim Group, and Roth Mkm.
View the latest analyst ratings for PBLA.

What is the current price target for Panbela Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Panbela Therapeutics in the last year. Their average twelve-month price target is $500.00, suggesting a possible upside of 42,272.9%. Roth Mkm has the highest price target set, predicting PBLA will reach $500.00 in the next twelve months. Roth Mkm has the lowest price target set, forecasting a price of $500.00 for Panbela Therapeutics in the next year.
View the latest price targets for PBLA.

What is the current consensus analyst rating for Panbela Therapeutics?

Panbela Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PBLA will outperform the market and that investors should add to their positions of Panbela Therapeutics.
View the latest ratings for PBLA.

What other companies compete with Panbela Therapeutics?

How do I contact Panbela Therapeutics' investor relations team?

Panbela Therapeutics' physical mailing address is 712 VISTA BLVD SUITE 305, WACONIA MN, 55387. The company's listed phone number is (952) 479-1196 and its investor relations email address is [email protected]. The official website for Panbela Therapeutics is www.panbela.com. Learn More about contacing Panbela Therapeutics investor relations.